Payment overview · 2025
General Payments
$442.44
23 reported records · 5 companies
Healthcare provider profile · identity verified
Simonne Maj Hammarquist, M.D.
Allopathic & Osteopathic Physicians|General Practice · NEW PORT RICHEY, FL · NPI 1033650551
Verified facts
What the public records show
CMS Open Payments records show Simonne Maj Hammarquist, M.D. received $442.44 in general payments during 2025 across 23 reported records.
Corcept Therapeutics accounted for 78.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $345.68 | 78.1% | 18 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.88 | 9.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.03 | 5.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.31 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.54 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $431.15 | 22 |
| Education | $11.29 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $345.68 | 18 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $41.88 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 103 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 348 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 257 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 212 | 61 |
| Losartan Potassium | Losartan Potassium | 206 | 66 |
| Lisinopril | Lisinopril | 195 | 60 |
| Omeprazole | Omeprazole | 193 | 63 |
| Metformin Hcl | Metformin Hcl | 189 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 55 |
| Gabapentin | Gabapentin | 166 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 48 |
| Trazodone Hcl | Trazodone Hcl | 135 | 40 |
| Furosemide | Furosemide | 127 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 35 |
| Meloxicam | Meloxicam | 116 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 46 |
| Eliquis | Apixaban | 103 | 17 |
| Simvastatin | Simvastatin | 103 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 23 |
| Buspirone Hcl | Buspirone Hcl | 80 | 36 |
| Alendronate Sodium | Alendronate Sodium | 76 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 18 |
| Glipizide | Glipizide | 57 | 19 |
| Sertraline Hcl | Sertraline Hcl | 57 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 18 |
| Ezetimibe | Ezetimibe | 51 | 17 |
| Memantine Hcl | Memantine Hcl | 51 | 11 |
| Montelukast Sodium | Montelukast Sodium | 51 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 21 |
| Cefdinir | Cefdinir | 48 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | suppressed |
| Januvia | Sitagliptin Phosphate | 46 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 16 |
| Donepezil Hcl | Donepezil Hcl | 44 | 11 |
| Carvedilol | Carvedilol | 42 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 16 |
| Methylprednisolone | Methylprednisolone | 41 | 35 |
| Potassium Chloride | Potassium Chloride | 40 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 14 |
| Glimepiride | Glimepiride | 38 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Atenolol | Atenolol | 31 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | 21 |
| Allopurinol | Allopurinol | 30 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 17 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $442.44 · 23 records | Corcept Therapeutics | ELIQUIS, Korlym, MOUNJARO, NURTEC ODT, The Cologuard Plus Collection Kit, UBRELVY, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error